These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18177462)

  • 21. Detecting and correcting the bias of unmeasured factors using perturbation analysis: a data-mining approach.
    Lee WC
    BMC Med Res Methodol; 2014 Feb; 14():18. PubMed ID: 24499374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteoporosis and anti-androgenic therapy in case of prostate cancer].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2261-2, 2264-5. PubMed ID: 16268448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect adjustment of relative risks of an exposure with multiple categories for an unmeasured confounder.
    Lubin JH; Hauptmann M; Blair A
    Ann Epidemiol; 2018 Nov; 28(11):801-807. PubMed ID: 30297163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Griebling TL
    J Urol; 2014 Feb; 191(2):388. PubMed ID: 24411874
    [No Abstract]   [Full Text] [Related]  

  • 26. [Confounder adjustment in observational comparative effectiveness researches: (2) statistical adjustment approaches for unmeasured confounders].
    Huang LL; Wei YY; Chen F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1450-1455. PubMed ID: 31838820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity analysis and power for instrumental variable studies.
    Wang X; Jiang Y; Zhang NR; Small DS
    Biometrics; 2018 Dec; 74(4):1150-1160. PubMed ID: 29603714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hierarchical priors for bias parameters in Bayesian sensitivity analysis for unmeasured confounding.
    McCandless LC; Gustafson P; Levy AR; Richardson S
    Stat Med; 2012 Feb; 31(4):383-96. PubMed ID: 22253142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of Bayesian and Monte Carlo sensitivity analysis for unmeasured confounding.
    McCandless LC; Gustafson P
    Stat Med; 2017 Aug; 36(18):2887-2901. PubMed ID: 28386994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjustment for unmeasured confounding through informative priors for the confounder-outcome relation.
    Groenwold RHH; Shofty I; Miočević M; van Smeden M; Klugkist I
    BMC Med Res Methodol; 2018 Dec; 18(1):174. PubMed ID: 30577773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the sensitivity of regression results to unmeasured confounders in observational studies.
    Lin DY; Psaty BM; Kronmal RA
    Biometrics; 1998 Sep; 54(3):948-63. PubMed ID: 9750244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the impact of unmeasured confounders for credible and reliable real-world evidence.
    Zhang X; Stamey JD; Mathur MB
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1219-1227. PubMed ID: 32929830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bounding the bias of unmeasured factors with confounding and effect-modifying potentials.
    Lee WC
    Stat Med; 2011 Apr; 30(9):1007-17. PubMed ID: 21472760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The missing cause approach to unmeasured confounding in pharmacoepidemiology.
    Abrahamowicz M; Bjerre LM; Beauchamp ME; LeLorier J; Burne R
    Stat Med; 2016 Mar; 35(7):1001-16. PubMed ID: 26932124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. unmconf : an R package for Bayesian regression with unmeasured confounders.
    Hebdon R; Stamey J; Kahle D; Zhang X
    BMC Med Res Methodol; 2024 Sep; 24(1):195. PubMed ID: 39244581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled direct and mediated effects: definition, identification and bounds.
    VanderWeele TJ
    Scand Stat Theory Appl; 2011 Sep; 38(3):551-563. PubMed ID: 25309023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed effects analysis of repeated measures data.
    Gunasekara FI; Richardson K; Carter K; Blakely T
    Int J Epidemiol; 2014 Feb; 43(1):264-9. PubMed ID: 24366487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.